National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Carglumic acid (Ucedane®). HTA ID: 22035

Carglumic acid (Ucedane®) is indicated for the treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency.

 

NCPE Assessment Process Complete
Rapid review commissioned 16/05/2022
Rapid review completed 21/06/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that carglumic acid (Ucedane®) not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.